Skip to main content
Equibles
SKYE logo

SKYE · Skye Bioscience, Inc. · Webcasts, Transcripts & Audio

Track SKYE — free

Use SKYE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SKYE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.67 -0.01 (-0.60%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$7.39M
Shares
4.43M
Volume · Oct 5 16.05K Avg daily vol (29 sessions) 82.67K

Skye Bioscience, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Skye Bioscience, Inc. (SKYE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Earnings call
FY25 · Q4
2026-03-10
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Positive tone CBEYOND clinical data and combination results Exposure/PK and biodistribution rationale Namasimab CB1 mechanism and differentiation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript
Confident tone CBEYOND Phase 2a top-line results Discovery R&D and CB1 mechanism Dose-ranging strategy and higher doses
Diluted EPS
$-2.56
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript
Confident tone Combination efficacy with tirzepatide Phase IIa clinical progress and timeline Market access and KOL feedback
Diluted EPS
$-3.52
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript
Positive tone Nimacimab Preclinical Data and Differentiation Combination Strategy with GLP-1 Phase 2b Trial Design
Diluted EPS
$-2.24
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
Confident tone nimacimab CBeyond clinical trial Safety profile and DSMB reviews Accelerated topline data timeline
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript
Confident tone Preclinical data and ObesityWeek disclosure GLP-1 / incretin landscape and combination potential Phase 2 CBeyond obesity clinical trial execution
Diluted EPS
$-0.80
Audio Transcript Slides 8-K10-Q
Showing 1–6 of 6 webcasts
Key facts CIK 1516551 CUSIP 83086J309 13F (30d) 1 filings 1 filers Visit website Investor relations